page-template-default,page,page-id-12981,page-child,parent-pageid-12411,strata-core-1.1.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.4,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-6.7.0,vc_responsive


One of the most promising US biotechnology companies, headquartered in Cambridge, Massachusetts, Alnylam concentrates on the discovery, development and commercialisation of RNA interference therapeutics for genetically defined diseases. The company joined a growing number of life science and healthcare businesses by establishing its European drug development and commercial headquarters in Maidenhead, welcoming positive messages of support from Prime Minister Theresa May, in whose constituency the investment lies. The firm also announced its intention to build a team of more than 100 employees, including scientific, medical and business staff.